Candriam S.C.A. Phathom Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

  • $17.1 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
SELL
$6.19 - $12.36 $121,194 - $241,996
-19,579 Reduced 23.49%
63,778 $455,000
Q4 2022

Feb 13, 2023
SELL
$9.18 - $11.53 $263,264 - $330,657
-28,678 Reduced 25.6%
83,357 $935,000
Q3 2022

Nov 10, 2022
BUY
$6.46 - $12.11 $723,746 - $1.36 Million
112,035 New
112,035 $1.24 Million

Others Institutions Holding PHAT

# of Institutions
144
Shares Held
73.6M
Call Options Held
42.3K
Put Options Held
45.7K
View Full List

About Phathom Pharmaceuticals, Inc.

PHAT Quotes by TradingView
  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $294M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email